StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1084.HK$0.67-4.29%
Fair $0.67+0.0%

1084.HK

Green Fresh Biotechnology Company Limited

Consumer Defensive / Farm ProductsHKSE

$0.67

-0.03 (-4.29%)

Fairly Valued+0.0%Fair Value $0.67Fund rank 22/100 · Data gapFallback financials|
SA 29/D
F-Score: 3/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $80.7M · quality 33.7/100

Data gap 22/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 10/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

29/100

D

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific biotech pipeline model required: targets are disabled until product, probability, peak-sales and cash-runway data exists. Revenue has declined for 3 consecutive years ROE is 0.8%, below the 5% threshold
Thesis & Journal · 1084.HKLocal privado en este navegador · Green Fresh Biotechnology Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$581M

P/E

67.0x

↑

EV/EBITDA

13.3x

↑

ROE

0.8%

↓

Gross Margin

18.5%

↓

Debt/Equity

0.71

↑
52-Week Range$1
$1$1

TradingView lightweight chart

1084.HK price, volumen y niveles de valoración

Último $0.670Periodo -50.4%
Fair value: $0.670

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-13.8%

FCF CAGR

—

FCF margin

-2.1%

FCF / Net income

-2.90x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $904.7M · net income $6.6M · FCF $-19.1M

2022-FY → 2025-FY

Gross margin

18.5%-8.7% pts

Operating margin

4.1%-16.5% pts

Net margin

0.7%-13.4% pts

FCF margin

-2.1%+2.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$904.7M$904.7M$989.3M$1.17B$1.41B
Net Income$6.6M$6.6M$62.2M$-85.3M$199.2M
EBITDA$81.8M$81.8M$158.8M$-28.8M$336.8M
EPS——0.07-0.100.24
Gross Margin18.5%18.5%22.5%3.2%27.2%
Operating Margin4.1%4.1%11.0%-6.2%20.6%
Net Margin0.7%0.7%6.3%-7.3%14.1%
Balance Sheet
Debt/Equity0.710.710.670.810.69
Current Ratio1.681.68———
Cash Flow
Free Cash Flow$-19.1M$-19.1M$80.7M$84.8M$-69.6M
Returns
ROE0.8%0.8%7.4%-11.4%23.6%
Valuation
P/E67.0067.009.86—16.04
EV/EBITDA13.2713.276.65—11.13
P/B0.690.690.730.813.79
Growth & Yield
Revenue Growth-8.5%-8.5%-15.7%-16.8%—
EPS Growth——171.8%-142.9%—
Dividend Yield1.7%1.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -6.5%

Total return

-6.5%

Start / end P/E

n/dx → n/dx

EPS bridge

0.07 → n/d

Residual

-8.2%

EPS growthn/d
Multiple reratingn/d
Dividend+1.7%
Residual / FX / buybacks / cross-term-8.2%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.